TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Mar 05, 2021 17:51 JST
Source:
Eisai
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease
TOKYO, Mar 05, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer's and Parkinson's Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.
Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.
Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab are being jointly developed by Eisai and Biogen.
Additionally, regarding the joint research effort with Sysmex Corporation for creation of simplified diagnosis of Alzheimer's disease (AD) using blood, a presentation is planned on new data regarding prediction of amyloid positivity through plasma Aß ratio measurement on a fully automated immunoassay incorporating APOE4 status, HISCLTM*.
In addition to presenting the latest data, Eisai and Biogen are planning to host a symposium focusing on the role of Aß in the AD pathology, entitled "The Science Behind the Aß Pathway in AD". Dr. Jeffrey Cummings, Dr. John Hardy, Dr. Colin Masters, and Dr. Philip Schelten, four renowned faculty in this field, will provide a discussion about the loss of Aß homeostasis as an early pathophysiological event within the AD continuum, along with a state-of-the-art presentation on the in vivo biomarkers of Aß.
Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia. Eisai strives to create innovative medicines as soon as possible to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, those living with the disease and their families.
*HISCLTM is a trademark of Sysmex Corporation.
Source: Eisai
Sectors: BioTech
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
April 14 2021 12:49 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
March 31 2021 20:22 JST
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
March 31 2021 20:18 JST
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
March 30 2021 11:42 JST
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021
March 26 2021 08:16 JST
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
March 23 2021 17:34 JST
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
March 22 2021 12:13 JST
Eisai Awarded The New Diversity Management Selection 100
March 22 2021 09:38 JST
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders
March 17 2021 10:05 JST
More Press release >>
Latest Press Release
Honda to Introduce First Energy Service for Europe - e:PROGRESS - in the UK
Apr 14, 2021 15:11 JST
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
Apr 14, 2021 13:49 JST
Mazda3 Named Canadian Car of the Year 2021
Apr 14, 2021 12:47 JST
Tokyo Century and DOCOMO to Globally Expand EDGEMATRIX Edge-AI Platform for Video Surveillance & Monitoring
Apr 13, 2021 17:57 JST
Fujitsu Renews Key Systems for Japan Meteorological Agency, Contributing to Completion of Centralized Virtualization Platform
Apr 13, 2021 15:28 JST
NEC recognized as a Partner of the Year by Juniper Networks for two consecutive years
Apr 13, 2021 11:52 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
Apr 12, 2021 13:16 JST
Fujitsu Embarks on Partnership with Siemens Digital Industries Software Strengthening Global Competitiveness and Accelerating DX to Realize Smart, Sustainable Manufacturing
Apr 12, 2021 11:48 JST
Lexus to Display LF-Z Electrified Concept and New ES
Apr 12, 2021 11:09 JST
MHI Invests in Starfire Energy, a Modular Green Ammonia Solution Provider, to Accelerate Efforts to Energy Transition
Apr 09, 2021 17:22 JST
DENSO Develops Advanced Driver Assistance Products for New Lexus LS, Toyota Mirai
Apr 09, 2021 13:46 JST
Deltacore Capital launches Deltacore Digital Global LP
Apr 09, 2021 13:30 JST
Hitachi Astemo to showcase advanced mobility solutions at Auto Shanghai 2021
Apr 09, 2021 13:05 JST
Overview of Honda and Acura Exhibits for Auto Shanghai 2021
Apr 08, 2021 15:25 JST
NEC and Cisco expand strategic partnership to help advance global deployments of 5G IP transport networks
Apr 08, 2021 14:26 JST
Toyota Launches LS and Mirai Equipped with "Advanced Drive" that Enables Drivers and Cars to Drive Together in Japan
Apr 08, 2021 13:40 JST
Fujitsu and Trend Micro Demonstrate Solution To Secure Private 5G
Apr 08, 2021 13:08 JST
DENSO Has Begun Testing CO2 Circulation Plant at Anjo Electrifica
Apr 07, 2021 17:24 JST
DENSO Transfers Its Aftermarket and Non-automotive Business to DENSO Solution
Apr 07, 2021 16:02 JST
Hitachi and Axcelead to start joint development of solutions for the efficient creation of next-generation biopharmaceuticals
Apr 07, 2021 15:32 JST
More Latest Release >>